iBio to Present at Major Investor Conferences
iBio, Inc. (NYSE: IBIO), a leader in the development of AI-driven precision antibody immunotherapies, has announced an exciting opportunity for investors. Martin Brenner, the CEO and Chief Scientific Officer, along with Chief Financial Officer Felipe Duran, will participate in several key upcoming conferences designed for investors and stakeholders.
Upcoming Conference Details
Dr. Martin Brenner is scheduled to deliver a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference. This event will be held at the esteemed Lotte New York Palace Hotel from September 9 to 11, 2024. Investors can access the on-demand presentation starting at 7 a.m. on September 9, and it will remain available for 30 days. For those interested in Dr. Brenner's insights, the presentation will also be archived in the investor section of iBio's website.
Details on Investor Meetings
In addition, iBio plans to connect with attendees at the 2024 Cantor Global Healthcare Conference, which will also occur in New York City from September 17 to 19, 2024. This conference serves as another significant opportunity to share the company's vision and innovations in the biopharmaceutical industry.
Scheduling One-on-One Meetings
For investors who prefer a more personalized discussion, one-on-one meetings with Dr. Brenner or Mr. Duran can be arranged by reaching out via email. This initiative is designed to enhance shareholder engagement and provide deeper insights into the company’s strategic direction and technological advancements in immunotherapy.
About iBio, Inc.
iBio is at the cutting edge of transforming healthcare through its innovative work in the biopharmaceutical sector. By employing advanced computational biology techniques and 3D modeling, iBio is dedicated to developing new antibody treatments aimed at difficult-to-treat cancers and other challenging diseases. The mission is straightforward: to reduce drug failures, speed up development timelines, and explore new opportunities against the most promising therapeutic targets. For more information on iBio's initiatives and projects, please visit their website.
Frequently Asked Questions
What is the main focus of iBio, Inc.?
iBio specializes in creating precision antibody immunotherapies using cutting-edge AI-driven technologies.
Who will represent iBio at the investor conferences?
CEO Martin Brenner and CFO Felipe Duran will represent iBio at the upcoming conferences.
What type of presentation will Dr. Brenner deliver?
Dr. Brenner will present virtually at the H.C. Wainwright Global Investment Conference, and it will be available on-demand for investors.
How can investors connect with iBio's leadership?
Investors can schedule one-on-one meetings by contacting the investor relations team at iBio via email.
Where can I find more information about iBio's innovations?
More information about iBio and its innovative biopharmaceuticals can be found on their official website.
